Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Haegarda for the Preventive Treatment of Hereditary Angioedema

Drug (Brand / Generic)

Haegarda®

Developer

CSL Behring

Therapy Class

C1-inhibitor replacement therapy

Current Indication

Hereditary angioedema (HAE)

Market Sector

Genetics

Development Status

Approved in the US
Expand

Go Top